Umut Elboga, Gulcin Elboga, Ceyhun Can, Ertan Sahin, Huseyin Karaoglan, Ebuzer Kalender, Hasan Deniz Demir, Mustafa Basibuyuk and Y Zeki Celen
Background: The aim of this study was to study objectively the level of anxiety and depression in patients undergoing positron emission tomography-computed tomography (PET-CT).One hundred and forty four oncologic out-patients (76 male, 68 female) were included in this study. Methods: All patients were referred to Nuclear Medicine Department for Fluorine-18 fluorodeoxyglucose (F-18 FDG) PET-CT imaging for the assessment of their malignant or possibly malignant diseases. The Hospital Anxiety Depression Scale and the State and Trait Anxiety Inventory I and II were used to evaluate the anxiety and depression levels in these patients. Results: The mean anxiety and depression scores of The Hospital Anxiety Depression Scale prior to F-18 FDG PET-CT were 9.2 ( ± 3.8) and 6.6 ( ± 3.4), respectively. The mean state and trait anxiety scores of the State and Trait Anxiety Inventory I and II prior to F-18 FDG PET-CT were 40.4 (± 8.5) and 46.62 ± 7.8, respectively. The Hospital Anxiety Depression Scale and the State and Trait Anxiety Inventory I and II anxiety scores were found to be significantly higher in female patients, smokers and in patients with higher stage disease. Conclusion: Our results suggest that F-18 FDG PET-CT imaging may at least contribute to patient’s baseline anxiety which is already generated by being an oncology patient, and thus nuclear medicine physicians should handle the patients with extra care to minimize this affect.